Major Depressive Disorder Clinical Trial
Official title:
A 52-week, Randomized, Double-blind, Placebo-controlled, Multi-center, Parallel-group Study of the Long-term Efficacy, Tolerability and Safety of Agomelatine 25 and 50 mg in the Prevention of Relapse of Major Depressive Disorder (MDD) Following Open-label Treatment of 16-24 Weeks
NCT number | NCT00467402 |
Other study ID # | CAGO178A2304 |
Secondary ID | |
Status | Completed |
Phase | Phase 3 |
First received | |
Last updated | |
Start date | April 2007 |
Verified date | May 2012 |
Source | Novartis |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study will demonstrate the efficacy of agomelatine (AGO178) 25 mg and 50 mg in the prevention of relapse in patients with Major Depressive Disorder (MDD). Eligible patients will undergo open-label treatment for 20 to 26 weeks, depending on response to treatment. Patients demonstrating stable response at the end of the open-label treatment phase will be assigned to receive agomelatine or placebo for 52 weeks.
Status | Completed |
Enrollment | 644 |
Est. completion date | |
Est. primary completion date | September 2009 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 70 Years |
Eligibility | Inclusion Criteria: - Male and female adults, 18 through 70 years of age, inclusive - Diagnosis of Major Depressive Disorder, recurrent episode, according to Diagnostic and Statistical Manual of Mental Disorders - 4th Edition (DSM-IV) criteria - A history of at least two previous episodes of Major Depression plus the current episode - Hamilton Depression Rating Scale (HAM-D17) total score = 22 at Screening and Baseline Exclusion Criteria: - History of bipolar disorder (I or II), schizophrenia, schizoaffective disorder, eating disorder, or obsessive compulsive disorder - Any current Axis I disorder other than major depressive disorder which is the focus of treatment - Substance or alcohol abuse in the last 30 days, dependence in the last 6 months - Use of any psychoactive medication after the screening visit - Patients who have been previously treated with agomelatine - Female patients of childbearing potential who are not using effective contraception Other protocol-defined inclusion/exclusion criteria may apply |
Country | Name | City | State |
---|---|---|---|
United States | Novartis Investigative Site | Albuquerque | New Mexico |
United States | Novartis Investigative Site | Allentown | Pennsylvania |
United States | Novartis Investigative Site | Atlanta | Georgia |
United States | Novartis Investigative Site | Austin | Texas |
United States | Novartis Investigative Site | Austin | Texas |
United States | Novartis Investigative Site | Beverly Hills | California |
United States | Novartis Investigative Site | Birmingham | Alabama |
United States | Novartis Investigative Site | Boston | Massachusetts |
United States | Novartis Investigative Site | Bradenton | Florida |
United States | Novartis Investigative Site | Braintree | Massachusetts |
United States | Novartis Investigative Site | Bronx | New York |
United States | Novartis Investigative Site | Buffalo | New York |
United States | Novartis Investigative Site | Chapel Hill | North Carolina |
United States | Novartis Investigative Site | Charleston | South Carolina |
United States | Novartis Investigative Site | Chicago | Illinois |
United States | Novartis Investigative Site | Chicago | Illinois |
United States | Novartis Investigative Site | Cleveland | Ohio |
United States | Novartis Investigative Site | Columbus | Ohio |
United States | Novartis Investigative Site | Coral Springs | Florida |
United States | Novartis Investigative Site | Costa Mesa | California |
United States | Novartis Investigative Site | DeSoto | Texas |
United States | Novartis Investigative Site | Edmonds | Washington |
United States | Novartis Investigative Site | Encino | California |
United States | Novartis Investigative Site | Farmington Hills | Michigan |
United States | Novartis Investigative Site | Fort Myers | Florida |
United States | Novartis Investigative Site | Gainesville | Florida |
United States | Novartis Investigative Site | Glendale | California |
United States | Novartis Investigative Site | Houston | Texas |
United States | Novartis Investigative Site | Houston | Texas |
United States | Novartis Investigative Site | Houston | Texas |
United States | Novartis Investigative Site | Jacksonville | Florida |
United States | Novartis Investigative Site | Kansas City | Missouri |
United States | Novartis Investigative Site | Kansas City | Missouri |
United States | Novartis Investigative Site | Lake Jackson | Texas |
United States | Novartis Investigative Site | Lansdale | Pennsylvania |
United States | Novartis Investigative Site | Libertyville | Illinois |
United States | Novartis Investigative Site | Los Angeles | California |
United States | Novartis Investigative Site | Memphis | Tennessee |
United States | Novartis Investigative Site | Milwaukee | Wisconsin |
United States | Novartis Investigative Site | Minneapolis | Minnesota |
United States | Novartis Investigative Site | Nashville | Tennessee |
United States | Novartis Investigative Site | New Orleans | Louisiana |
United States | Novartis Investigative Site | New York | New York |
United States | Novartis Investigative Site | New York | New York |
United States | Novartis Investigative Site | Newark | New Jersey |
United States | Novartis Investigative Site | Newport Beach | California |
United States | Novartis Investigative Site | Oceanside | California |
United States | Novartis Investigative Site | Omaha | Nebraska |
United States | Novartis Investigative Site | Overland Park | Kansas |
United States | Novartis Investigative Site | Peoria | Arizona |
United States | Novartis Investigative Site | Philadelphia | Pennsylvania |
United States | Novartis Investigative Site | Pittsburgh | Pennsylvania |
United States | Novartis Investigative Site | Pittsburgh | Pennsylvania |
United States | Novartis Investigative Site | Portland | Oregon |
United States | Novartis Investigative Site | Portland | Oregon |
United States | Novartis Investigative Site | Raleigh | North Carolina |
United States | Novartis Investigative Site | Rhododendron | Oregon |
United States | Novartis Investigative Site | Richmond | Virginia |
United States | Novartis Investigative Site | Rockville | Maryland |
United States | Novartis Investigative Site | Sacramento | California |
United States | Novartis Investigative Site | Saint Louis | Missouri |
United States | Novartis Investigative Site | Saint Louis | Missouri |
United States | Novartis Investigative Site | Saint Louis | Missouri |
United States | Novartis Investigative Site | Saint Petersburg | Florida |
United States | Novartis Investigative Site | Seattle | Washington |
United States | Novartis Investigative Site | Sherman Oaks | California |
United States | Novartis Investigative Site | Temecula | California |
United States | Novartis Investigative Site | Toledo | Ohio |
United States | Novartis Investigative Site | Topeka | Kansas |
United States | Novartis Investigative Site | Towson | Maryland |
United States | Novartis Investigative Site | Towson | Maryland |
United States | Novartis Investigative Site | Tucson | Arizona |
United States | Novartis Investigative Site | Venice | Florida |
United States | Novartis Investigative Site | Virginia Beach | Virginia |
United States | Novartis Investigative Site | West Allis | Wisconsin |
United States | Novartis Investigative Site | West Palm Beach | Florida |
United States | Novartis Investigative Site | Wheat Ridge | Colorado |
United States | Novartis Investigative Site | Worcester | Massachusetts |
Lead Sponsor | Collaborator |
---|---|
Novartis |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Time to relapse, where relapse is defined by the occurrence of any one of the following: | Primary efficacy variable is measured from randomization to relapse | ||
Primary | Hamilton Depression Rating Scale total score =16 at two consecutive visits; | Primary efficacy variable is measured from randomization to relapse | ||
Primary | hospitalization due to depression; | Primary efficacy variable is measured from randomization to relapse | ||
Primary | suicide attempt or suicide; | Primary efficacy variable is measured from randomization to relapse | ||
Primary | discontinuation due to lack of efficacy according to Investigator judgment. | Primary efficacy variable is measured from randomization to relapse | ||
Secondary | Proportion of patients who demonstrate clinical improvement at the end of the double-blind continuation phase, where improvement is defined by a score of 1 or 2 on the Clinical Global Impression Improvement (CGI-I) scale. | Secondary efficacy variables will be measured from randomization to the end of the Double-Blind continuation Phase | ||
Secondary | Proportion of patients experiencing relapse during the double-blind continuation phase. | Secondary efficacy variables will be measured from randomization to the end of the Double-Blind continuation Phase | ||
Secondary | Proportion of patients who achieve remission at the end of the double-blind continuation phase, where remission is defined by a total score of =7 on the HAM-D. | Secondary efficacy variables will be measured from randomization to the end of the Double-Blind continuation Phase | ||
Secondary | Change from randomization to the end of the double-blind continuation phase, on the Hospital Anxiety and Depression (HAD) total score and subscale scores. | Secondary efficacy variables will be measured from randomization to the end of the Double-Blind continuation Phase |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05537558 -
Precision Medicine for the Prediction of Treatment (PROMPT) Response (PROMPT)
|
||
Terminated |
NCT02192099 -
Open Label Extension for GLYX13-C-202, NCT01684163
|
Phase 2 | |
Completed |
NCT03142919 -
Lipopolysaccharide (LPS) Challenge in Depression
|
Phase 2 | |
Recruiting |
NCT05547035 -
Identification of Physiological Data by a Wearable Monitor in Subjects Suffering From Major Depression Disorders
|
N/A | |
Terminated |
NCT02940769 -
Neurobiological Effects of Light on MDD
|
N/A | |
Recruiting |
NCT05892744 -
Establishing Multimodal Brain Biomarkers for Treatment Selection in Depression
|
Phase 4 | |
Recruiting |
NCT05537584 -
SMART Trial to Predict Anhedonia Response to Antidepressant Treatment
|
Phase 4 | |
Active, not recruiting |
NCT05061706 -
Multicenter Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
|
Phase 3 | |
Completed |
NCT04479852 -
A Study of the Safety and Efficacy of SP-624 in the Treatment of Adults With Major Depressive Disorder
|
Phase 2 | |
Recruiting |
NCT04032301 -
Repeated Ketamine Infusions for Comorbid PTSD and MDD in Veterans
|
Phase 1 | |
Recruiting |
NCT05527951 -
Enhanced Measurement-Based Care Effectiveness for Depression (EMBED) Study
|
N/A | |
Completed |
NCT03511599 -
Cycloserine rTMS Plasticity Augmentation in Depression
|
Phase 1 | |
Recruiting |
NCT04392947 -
Treatment of Major Depressive Disorder With Bilateral Theta Burst Stimulation
|
N/A | |
Recruiting |
NCT05895747 -
5-HTP and Creatine for Depression R33 Phase
|
Phase 2 | |
Recruiting |
NCT05273996 -
Predictors of Cognitive Outcomes in Geriatric Depression
|
Phase 4 | |
Recruiting |
NCT05813093 -
Interleaved TMS-fMRI in Ultra-treatment Resistant Depression
|
N/A | |
Recruiting |
NCT05135897 -
The Neurobiological Fundaments of Depression and Its Relief Through Neurostimulation Treatments
|
||
Enrolling by invitation |
NCT04509102 -
Psychostimulant Augmentation of Repetitive TMS for the Treatment of Major Depressive Disorder
|
Early Phase 1 | |
Recruiting |
NCT06145594 -
EMA-Guided Maintenance TMS for Depression
|
N/A | |
Recruiting |
NCT06026917 -
Assessing Dopamine Transporter Occupancy in the Patients With Depression Brain With Toludesvenlafaxine Hydrochloride Extended-Release Tablets Using 11C-CFT Positron Emission Tomography (PET)
|
Phase 4 |